CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

Colossal, values the Dallas-based startup at a staggering $10.2 billion. Besides making it the first startup founded in Texas ...

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company at the forefront of precision genetic medicines with a market capitalization of $1.87 billion, is navigating a critical juncture in its ...

In a new paper in Nature Communications, researchers in the Center for Precision Engineering for Health (CPE4H) at the ...

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day. Subscribe for FREE Capable of precisely editing genes, activating gene expression ...

UK ministers are pressing ahead with legislation to adopt gene editing technology despite warnings from Brussels that it ...

Genetic engineering startup Colossal announced Wednesday it had reached a $10 billion valuation, the first startup in Texas ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...

The scientific team at the laboratory is headed by a group of women with a track record in genomic science, molecular ...

The UK’s plans to adopt the latest gene editing technology face delays over fears they will clash with EU law if Downing ...